MedPath

Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Clinical Trials
Related News

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

First Posted Date
2024-01-05
Last Posted Date
2025-04-30
Lead Sponsor
Genmab
Target Recruit Count
1095
Registration Number
NCT06191744
Locations
🇫🇷

Hôpital Saint-Louis /ID# 260509, Paris, France

🇫🇷

Clinique Sainte-Anne /ID# 261528, Strasbourg, France

🇨🇳

Zhujiang Hospital of Southern Medical University /ID# 260558, Guangzhou, Guangdong, China

and more 217 locations

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

First Posted Date
2024-01-03
Last Posted Date
2024-01-03
Lead Sponsor
National Research Center for Hematology, Russia
Target Recruit Count
100
Registration Number
NCT06188676
Locations
🇷🇺

National Research Center for Hematology, Moscow, Russian Federation

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting
Conditions
Philadelphia-Positive ALL
Lymphoblastic Leukemia
Adult ALL
Interventions
Procedure: allogeneic stem cell transplantation
Procedure: Total body irradiation
First Posted Date
2023-12-19
Last Posted Date
2023-12-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
150
Registration Number
NCT06175702

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3
Recruiting
Conditions
Ganglioneuroblastoma, Nodular
Neuroblastoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
Procedure: Hematopoietic Cell Transplantation
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Radiation: Radiation Therapy
Procedure: Radionuclide Imaging
Other: Survey Administration
Procedure: Tumor Resection
First Posted Date
2023-12-15
Last Posted Date
2025-05-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
478
Registration Number
NCT06172296
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 150 locations

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 3
Not yet recruiting
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Radiation: Radiation Therapy
First Posted Date
2023-11-09
Last Posted Date
2025-04-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
680
Registration Number
NCT06124157

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Phase 3
Recruiting
Conditions
Follicular Lymphoma (FL)
Interventions
Drug: Prednisone/Prenisolone
First Posted Date
2023-10-24
Last Posted Date
2025-04-24
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
733
Registration Number
NCT06097364
Locations
🇮🇱

The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

🇮🇱

Assuta Medical Centers, Tel Aviv, Israel

🇮🇹

University of Pisa, Section of Hematology, Pisa, Italy

and more 104 locations

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Phase 3
Active, not recruiting
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Drug: Prednisone/Prednisolone
First Posted Date
2023-10-19
Last Posted Date
2025-05-15
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
904
Registration Number
NCT06091865
Locations
🇰🇷

Seoul St Marys Hospital, Seoul, Korea, Republic of

🇲🇾

Hospital Ampang, Ampang, Pahang, Malaysia

🇪🇸

Hospital General Universitario de Toledo, Toledo, Spain

and more 146 locations

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

Phase 3
Recruiting
Conditions
Follicular Lymphoma (FL)
Interventions
Drug: Prednisone/prednisolone
First Posted Date
2023-10-19
Last Posted Date
2025-05-20
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
478
Registration Number
NCT06091254
Locations
🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

HOPE Cancer Center of East Texas, Tyler, Texas, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 168 locations

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Phase 2
Recruiting
Conditions
Large B-cell Lymphoma
Interventions
First Posted Date
2023-09-21
Last Posted Date
2025-03-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT06045247
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Phase 2
Recruiting
Conditions
Rhabdomyosarcoma
Interventions
Procedure: Surgical Resection
Procedure: Proton beam radiation or external beam radiation or brachytherapy
First Posted Date
2023-09-05
Last Posted Date
2025-05-18
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
135
Registration Number
NCT06023641
Locations
🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

🇺🇸

Sanford University, Palo Alto, California, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy